Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic

Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic, a Society of Toxicology Contemporary Concepts in Toxicology (CCT) workshop was held on March 11, 2017. The meeting was convened to raise awareness of metabolic syndrome and its associated diseases and serve as a melting pot wi...

Full description

Saved in:

Bibliographic Details
Published in:	Toxicological sciences Vol. 162; no. 1; p. 36
Main Authors:	Mendrick, Donna L, Diehl, Anna Mae, Topor, Lisa S, Dietert, Rodney R, Will, Yvonne, La Merrill, Michele A, Bouret, Sebastien, Varma, Vijayalaskshmi, Hastings, Kenneth L, Schug, Thaddeus T, Emeigh Hart, Susan G, Burleson, Florence G
Format:	Journal Article
Language:	English
Published:	United States 01.03.2018
Subjects:	Animals Biomedical Research - methods Biomedical Research - trends Clinical Medicine - methods Clinical Medicine - trends Drug-Related Side Effects and Adverse Reactions - etiology Drug-Related Side Effects and Adverse Reactions - genetics Drug-Related Side Effects and Adverse Reactions - immunology Environmental Pollutants - toxicity Humans Life Style Metabolic Syndrome - chemically induced Metabolic Syndrome - etiology Metabolic Syndrome - genetics Metabolic Syndrome - immunology
ISSN:	1096-0929, 1096-0929
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Metabolic Syndrome and Associated Diseases: From the Bench to the Clinic, a Society of Toxicology Contemporary Concepts in Toxicology (CCT) workshop was held on March 11, 2017. The meeting was convened to raise awareness of metabolic syndrome and its associated diseases and serve as a melting pot with scientists of multiple disciplines (eg, toxicologists, clinicians, regulators) so as to spur research and understanding of this condition. The criteria for metabolic syndrome include obesity, dyslipidemia (low high-density lipoprotein and/or elevated triglycerides), elevated blood pressure, and alterations in glucose metabolism. It can lead to a greater potential of type 2 diabetes, lipid disorders, cardiovascular disease, hepatic steatosis, and other circulatory disorders. Although there are no approved drugs specifically for this syndrome, many drugs target diseases associated with this syndrome thus potentially increasing the likelihood of drug-drug interactions. There is currently significant research focusing on understanding the key pathways that control metabolism, which would be likely targets of risk factors (eg, exposure to xenobiotics, genetics) and lifestyle factors (eg, microbiome, nutrition, and exercise) that contribute to metabolic syndrome. Understanding these pathways could also lead to the development of pharmaceutical interventions. As individuals with metabolic syndrome have signs similar to that of toxic responses (eg, oxidative stress and inflammation) and organ dysfunction, these alterations should be taken into account in drug development. With the increasing frequency of metabolic syndrome in the general population, the idea of a "normal" individual may need to be redefined. This paper reports on the substance and outcomes of this workshop.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	1096-0929 1096-0929
DOI:	10.1093/toxsci/kfx233